Instruction for use: Xantinol nicotinate

Trade name of the drug – Complamin, Xantinol nicotinate, Xantinol nicotinate-UBF, Xantinol nicotinate solution for injections 15%, Xantinol nicotinate tablets 0,15 g.

The Latin name of the substance Xantinol nicotinate

Xantinoli nicotinas (genus. Xantinoli nicotinatis*)

Chemical name

3,7-Dihydro-7- [2-hydroxy-3 - [(2-hydroxyethyl) methylamino] propyl] -1,3-dimethyl-1H-purin-2,6-dione with nicotinic acid

Gross formula

C13H21N5O4.C6H5NO2

Pharmacological group:

Antiaggregants

Nicotinates

Angioprotectors and microcirculatory correctors

Vasodilators

Correctors of cerebral circulation disorders

The nosological classification (ICD-10)

E78.0 Pure hypercholesterolemia: Heterozygous hereditary hypercholesterolemia; Heterozygous non-family hypercholesterolemia; Heterozygous familial hypercholesterolemia; Hypercholesterolemia; Hypercholesterolemia primary; Homozygous familial hypercholesterolemia; Homozygous sitosterolemia; Isolated endogenous hypercholesterolemia; Elevated cholesterol; Elevated blood cholesterol levels; Family hypercholesterolemia; Phytosterolemia Endogenous hypercholesterolemia; Primary hypercholesterolemia; Family Hypercholesterolemia Mixed

E78.1 Pure hyperglyceridemia: Hyperglyceridemia; Hypertriglyceridemia; Essential hypertriglyceridemia; Endogenous hypertriglyceridemia; Family endogenous hypertriglyceridemia; Primary hyperlipidemia

G43 Migraine: The pain of migraine; Migraine; hemiplegic migraine; Migraine headache; A migraine attack; Continuous headache; hemicranias

H36.0 Diabetic retinopathy (E10-E14 + with common fourth character .3): Haemorrhagic diabetic retinopathy; Diabetic retinopathy; Macular degeneration in patients with diabetes

H81.0 Meniere's disease: Meniere's syndrome/ disease; Meniere's disease; Meniere's syndrome; Labyrinth dropsy; endolymphatic hydrops

I25.1 Atherosclerotic heart disease: Atherosclerosis and the likelihood of reinfarction; Atherosclerosis of the coronary vessels; Atherosclerotic heart disease; Atherosclerotic cardio; The coronary atherosclerosis; cardiosclerosis; cardiosclerosis atherosclerotic; Coronary atherosclerosis; Coronary atherosclerosis in patients with coronary artery disease; koronaroskleroza; Myocardial ischemia, arteriosclerosis

I63 Cerebral infarction: ischemic Stroke; Ischemic brain disease; Ischemic stroke; Ischemic stroke and its consequences; Ischemic cerebral stroke; Ischemic cerebrovascular accident; Ischemic brain damage; Ischemic brain damage; ischemic conditions; Cerebral ischemia; Acute hypoxia brain; Acute cerebral ischemia; Acute ischemic cerebrovascular accident; Acute cerebral infarction; Acute ischemic stroke; Acute period of ischemic stroke; Focal cerebral ischemia; Ischemic stroke; recurrent stroke; The syndrome of Morgagni-Adams-Stokes; Chronic cerebral ischemia; cerebrovascular stroke; embolic stroke; Ischemic brain damage

I67.2 Cerebral atherosclerosis: Atherosclerosis of the arteries of the brain; Atherosclerosis of cerebral vessels; Atherosclerotic changes in cerebral vessels; Vascular diseases of the brain; Sclerotic ischemic attacks; Sclerosis of cerebral vessels

I70 Atherosclerosis: Atherosclerosis; Atherosclerosis of peripheral vessels; Atherosclerotic changes; Atherosclerotic vascular changes; Atherosclerotic disorders; spontaneous; Trombangioz obliterans; Frinlendera disease

I70.2 Atherosclerosis of arteries: arteriosclerosis obliterans; Arteriosclerosis peripheral arteries; Atherosclerosis of the arteries of the lower extremities; Atherosclerosis of peripheral arteries; Atherosclerosis limbs; Occlusive disease of the lower extremities; arteriosclerosis obliterans; Arteriosclerosis obliterans of lower limb arteries; Atherosclerosis obliterans of the upper limbs; Arteriosclerosis obliterans of lower extremities; Atherosclerosis of arteries; limb arteriopathy; Arteriosclerosis obliterans limbs; arteriosclerosis obliterans

I73.0 Raynaud's Syndrome: Raynaud's syndrome Leriche; Raynaud's disease; Raynaud's phenomenon; RaynaudLeriche syndrome; Raynaud's disease; Raynaud's syndrome with trophic disorders; Peripheral angiopathy

I73.1 thromboangiitis obliterans [Buerger's disease]: Berger's disease; thromboangiitis obliterans; trombangiit; thromboangiitis obliterans; Buerger's disease

I74 Embolism and arterial thrombosis: Thrombosis of effort (stress); Arterial thrombosis; Arteriothrombosis; Subacute and chronic arterial thrombosis; Subacute thrombosis of peripheral arteries; Postoperative thrombosis; Vascular thrombosis; Vascular embolism; Thrombosis of aortocoronary shunt; Arterial thrombosis; Thrombosis of arteries; Coronary artery thrombosis; Coronary thrombosis; Thrombosis of blood vessels; Thrombosis with ischemic stroke; Thrombosis with general surgical operations; Thrombosis in Oncology Operations; Vascular thrombosis; Thrombus formation in the postoperative period; Thrombotic complications; Thromboembolic diseases; Thromboembolic syndrome; Thromboembolic complication in the postoperative period; Thromboembolism of arteries; Partial vascular thrombosis; Embolism; Embolism of arteries

I77.1 arteriostenosis: Occlusive arterial disease; Peripheral arterial occlusive disease;Peripheral arterial occlusive disease in stages III-IV on Fontaine

I79.2 Peripheral angiopathy in diseases classified elsewhere: diabetic angiopathy; Angiopathy in diabetes; arteriosclerosis diabetic; Pain in lesions of peripheral nerves; Diabetic angiopathy; Diabetic microangiopathy; Diabetic vascular disease; Intermittent angioneurotic disbaziya; Macroangiopathy in diabetes; microangiopathy; Microangiopathy in diabetes mellitus; Tingling sensations in the hands and feet; Coldness in the extremities; Peripheral angiopathy; Peripheral arterial disease; Sclerosis Menkeberga; Chronic obliterating diseases of arteries

I80 Phlebitis and thrombophlebitis: Diseases of peripheral vessels; Inflammation of superficial veins; Inflammatory diseases of veins; Deep venous thrombophlebitis; The disease of veins; Disease of the veins of the lower extremities; Diseases of peripheral vessels; Migrating phlebitis; Insufficiency of veins of lower extremities; Exacerbation of chronic thrombophlebitis; Acute thrombophlebitis; Acute thrombophlebitis of superficial veins; Periphlebitis; Periflebit surface; Superficial inflammation of veins; Surface thrombophlebitis; Surface phlebitis; Thrombophlebitis; Deep vein thrombophlebitis; Thrombophlebitis superficial; Phlebitis; Phlebitis of deep veins; Phlebitis of superficial veins; Phlebopathy; Chronic thrombophlebitis; Endophlebitis

L89 Decubital ulcer: Decubital gangrene; Bedsores; Bedsore; Secondary-infected bedsores; Gangrene decubital

L90.8 Other atrophic skin changes: Congenital disckeratosis; Skin Trophism; Skin aging; Increased dryness of the skin

L98.9 Skin and subcutaneous tissue disorders, unspecified: Adiponecrosisæ Atonic leatheræ Diseases of the skinæ Blisteræ Inflammatory disease of soft tissuesæ Inflammatory processes of epithelial tissuesæ Degenerative changes in the skin and mucous membranesæ Degenerative changes in the skin and mucous membranesæ Excess granulationæ Thinning of the skinæ Skin diseaseæ Maceration of the skinæ Minor skin lesionsæ Surface crack and skin abrasionæ Increased skin peelingæ Skin lesionæ Erosion of the skinæ Lipedemaæ Local non-infectious processes of skin and soft tissuesæ Disturbance of the structure of the skinæ Dysfunction of the skinæ Skin disorders

P20 Intrauterine hypoxia: Fetal intrauterine fetal asphyxiaæ Intrauterine fetal asphyxiaæ Hypoxia of the fetus

P21 Asphyxiation during labor: Asphyxia of infant; Consequence of asphyxia of infant

T14.1 Open wound of unspecified body region: Secondary healing processes; Sluggishly granulating wounds; Sluggishly healing wounds; Sluggish wounds; Deep Wounds; Purulent wound; Granulating wounds; Prolonged non-healing wound; Long-lasting non-healing wound and ulcer; Long-lasting non-healing soft tissue wound; Healing of wounds; Wound healing; Capillary bleeding from superficial wounds; Bleeding wound; Radiation Wounds; Slowly epithelializing wounds; Minor cuts; Suppurated wounds; Violation of wound healing processes; Breach of skin integrity; Violations of the integrity of the skin; Violations of the integrity of the skin; Small cuts; Uninfected wounds; Uncomplicated wounds; Operating wound; Primary treatment of surface contaminated wounds; Primary wound treatment; Primary-delayed treatment of wounds; Poorly cicatrizing wound; Poor wound healing; Bad wound; Superficial injury; Superficial wound with mild exudation; Wound; The wound is large; Bite wound; Wound process; Wounds; Wound healing wounds; Stump Wounds; Wounds for gunshot; Wounds with deep cavities; Difficult healing wounds; Difficult wounds; Chronic Wounds

CAS Code

437-74-1

Characteristics of the substance Xantinol nicotinate

White crystalline powder. Easily soluble in water, little - in alcohol.

Pharmacology

Mode of action - Vasodilator, antiaggregational, antiatherosclerotic.

It blocks adenosine receptors and phosphodiesterase, increasing the level of cAMP in the cell, stimulates the synthesis of nicotinadenine dinucleotide (NAD) and NAD-phosphate. It has a vasodilating effect, reduces OPSS, inhibits platelet aggregation, improves microcirculation, oxygenation and nutrition of tissues, enhances cerebral circulation, reduces blood viscosity, activates fibrinolysis; With prolonged use is able to delay the development of atherosclerosis, reduces the level of cholesterol and atherogenic lipids, enhances the activity of lipoprotein lipase.

Application of substance of the Xantinol nicotinate

Disorders of cerebral circulation, cerebral atherosclerosis, obliterating atherosclerosis of lower extremity vessels, Raynaud's disease, Burger's disease, obliterating endarteritis, acute arterial thrombosis, diabetic angiopathy, retinopathy, acute thrombophlebitis (of superficial and deep veins), postthrombophlebitic syndrome, trophic ulcers of lower extremities, pressure ulcers , Migraine, Meniere's syndrome, dermatosis (due to disturbed vascular genesis), coronary atherosclerosis, hypercholesterolemia, hypertriglyceridemia, intrauterine and postpartum fetal asphyxia

Contraindications for Xantinol nicotinate

Hypersensitivity, severe congestive heart failure, acute bleeding, acute myocardial infarction, peptic ulcer of the stomach and duodenum in the stage of exacerbation.

Restrictions

Arterial hypotension, pregnancy (especially in the first trimester).

Side effect of Xantinol nicotinate

Arterial hypotension, transient sensation of heat, redness of the skin, weakness, dizziness, nausea, diarrhea, anorexia, gastralgia. With long-term administration of high doses, a decrease in glucose tolerance, an increase in hepatic transaminase and alkaline phosphatase activity, hyperuricemia.

Interaction

Strengthens (mutually) the effect of antihypertensive drugs (beta-adrenoblockers, ergot alkaloids, alpha-adrenoblockers, sympatholytics, ganglioblocators).

Routes of administration

Inside, intramusculary, intravenous (by stream infusion or by drop infusion).

Precautions for the substanceof Xantinol nicotinate

Caution should be exercised with simultaneous administration with antihypertensive agents and strophanthin.